The external environment surrounding the ethical drug business is becoming more severe due to further strengthening measures to control medical expenses and drug costs, increasing difficulty in creating new drugs, and changes in drug sales promotion activities. On the other hand, in terms of the internal environment, new drugs group that are expected as growth drivers are all present, and the diagnosis business is budding, which are considered to be the start of the growth period. Under these circumstances, in order to pursue our “originality (original competitive edge)” that is not the conventional way of thinking and method, and to realize the shift to the growth trend, we established the new medium-term business plan “HOPE100-Stage3-”. We set the statement "Achieve growth trends by pursuing originality", work on business strategies and organization strategies, and strive to achieve the key performance targets.
Medium-Term Business Plan